OncRef
Skip to newsletter content
|
SCLCAugust 2026
0:00 / 2:24
Small Cell Lung Cancer — Monthly Compass
Aug 01–31, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in small cell lung cancer this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
small cell lung cancer updates
Key Highlights
Key Highlights
  • Practice-Changing Updates
    • Jazz Pharmaceuticals will file a prior approval labeling supplement in 3Q26 to withdraw Zepzelca’s accelerated‑approval second‑line metastatic SCLC indication after the phase 3 LAGOON OS miss, while the first‑line maintenance use with atezolizumab remains unchanged.
  • Key Clinical Development Updates
    • IDEAYA secured FDA Type C alignment for IDE849 (DLL3 TOP1 ADC) on a randomized phase 3 ES‑SCLC trial starting by year‑end 2026 that uses ORR by BICR for potential Accelerated Approval and median OS for potential full approval.
  • Key Conference Updates
    • August pre‑WCLC disclosures in SCLC emphasize acceleration of ADCs targeting SEZ6/DLL3/B7‑H3, emergence of bispecific immunomodulator combinations, and expansion of DLL3 T‑cell engagers into earlier settings, signaling imminent registrational moves and evolving sequencing beyond tarlatamab.
    • WCLC 2026 is slated to deliver first data for the pumitamig plus elfetabart drozuntecan combination, multiple ABBV‑706 safety/biomarker presentations, and Amgen dosing‑interval and combination updates.
  • Emerging Themes & Macro-Trends
    • Topo‑I payload ADCs centered on lineage antigens are gaining momentum with high ORR signals for ABBV‑706 in relapsed/refractory SCLC and broad targetability supported by SEZ6 expression around 91% overall and above 96% in brain and liver metastases.
    • Strategic focus is shifting toward antigen‑directed sequencing (DLL3→SEZ6/B7‑H3), proactive management of overlapping toxicities from Topo‑I payloads and IL‑2 add‑ons, and expansion of SEZ6/DLL3 diagnostic access to capture broad SCLC segments.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • There are no press releases between 2026-08-01 and 2026-08-31 about small cell lung cancer.
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • Jazz Pharmaceuticals said it will submit a prior approval labeling supplement to the FDA in 3Q26 to remove Zepzelca (lurbinectedin)’s second-line metastatic SCLC indication after the confirmatory phase 3 LAGOON trial missed its OS end point; the company noted the first-line maintenance indication with atezolizumab remains unaffected. The report emphasizes that the second-line indication had been granted under FDA’s Accelerated Approval and is now planned for withdrawal in alignment with FDA. ¹ (read more)
  • Oncology News Central reported that Jazz is voluntarily withdrawing lurbinectedin’s second-line SCLC indication and will file a prior approval labeling supplement in 3Q26 following LAGOON’s failure to confirm benefit under Accelerated Approval; the first-line maintenance indication remains intact. The article recaps the regulatory context and notes FDA’s prior accelerated approval in 2020 for the second-line use. ² (read more)
  • IDEAYA Biosciences announced a successful FDA Type C meeting for IDE849 (DLL3 TOP1 ADC) defining a randomized phase 3 registrational trial in ES-SCLC targeted to start by year-end 2026. The study is designed with ORR by BICR as the primary end point for potential Accelerated Approval and median OS as the primary end point for potential full approval. ³ (read more)
Conference
Major Conference Updates
Conference Information
  • IASLC 2026 World Conference on Lung Cancer (WCLC), Seoul, Republic of Korea; September 12–15, 2026. (read more)
  • August pre‑WCLC disclosures in SCLC emphasize ADC acceleration (SEZ6, DLL3, B7‑H3), novel bispecific immunomodulators, and DLL3 T‑cell engager expansion into earlier settings—signaling imminent registrational moves and evolving sequencing beyond tarlatamab. (read more)
  • Theme 1: ADCs Targeting Lineage Antigens Gain Speed (SEZ6, DLL3, B7-H3)
    • Significance: ADC momentum is building with new efficacy signals and clear regulatory paths; biomarker prevalence supports broad reach (SEZ6 expression ~91% overall, >96% in brain/liver mets). (read more)
    • Mechanism insights / clinical impact: Topo‑I payload ADCs (ABBV‑706; IDE849) exploit SEZ6/DLL3; ABBV‑706 shows high ORR in R/R SCLC with generally manageable hematologic/GI toxicity and low ILD signal; IDE849 targets Phase 3 with ORR (BICR) for accelerated approval. (read more)
    • Patient populations affected: Relapsed/refractory ES‑SCLC (including post‑tarlatamab) and patients with metastatic burden (brain/liver) where SEZ6 is enriched; early combination strategies extend to NSCLC/SCLC via B7‑H3 ADC elfetabart drozuntecan. (read more)
  • Theme 2: Novel‑Novel Combinations Blend Immunomodulation and Cytotoxicity
    • Significance: Combinations aim to overcome immune suppression (PD‑L1/VEGF‑A axis) and antigen heterogeneity by pairing bispecific immunomodulators with ADCs—positioning for first‑data inflection at WCLC. (read more)
    • Mechanism insights / clinical impact: Pumitamig (BNT327/BMS986545) + elfetabart drozuntecan (BNT324/DB‑1311) (NCT06892548) unites vascular normalization/immune priming with B7‑H3–directed payload delivery; Amgen is similarly testing tarlatamab with B7‑H3 ADC YL201 and with IL‑2 (etakafusp alfa). (read more)
    • Patient populations affected: Advanced/metastatic SCLC (and NSCLC) in early‑phase combination cohorts; potential move upstream into 1L paradigms depending on safety/efficacy readouts. (read more)
  • Theme 3: DLL3 T‑Cell Engagers Expand into Earlier Settings and New Formats
    • Significance: Program breadth (maintenance, LS‑SCLC post‑CCRT, induction/maintenance 1L ES‑SCLC) and delivery innovations (subcutaneous; extended‑interval IV) suggest meaningful access and durability gains. (read more)
    • Mechanism insights / clinical impact: Tarlatamab redirects T cells to DLL3; ongoing Phase 3s (DeLLphi‑305 maintenance; DeLLphi‑306 post‑CCRT LS‑SCLC; DeLLphi‑312 1L induction/maintenance) plus combo trials (YL201 ADC; etakafusp alfa) create multiple shots on goal. (read more)
    • Patient populations affected: 1L ES‑SCLC (maintenance/induction‑maintenance), LS‑SCLC post‑chemoradiation, and 2L+ ES‑SCLC—including potential convenience benefits from SC dosing. (read more)
  • Significance
    • Expected clinical or translational readouts: First data for pumitamig + elfetabart drozuntecan at WCLC; multiple ABBV‑706 safety/biomarker presentations; Amgen dosing‑interval and combination updates at upcoming meetings. (read more)
    • Regulatory or policy implications: IDE849 Type C alignment supports a single Phase 3 enabling accelerated/full approval in ES‑SCLC; watch for breakthrough or expedited pathways as datasets mature. (read more)
    • Potential shifts in standard of care: Positive DLL3 TCE Phase 3s in maintenance/LS‑SCLC could reframe early settings; ADCs may become preferred post‑tarlatamab options, guided by SEZ6/DLL3/B7‑H3 profiling. (read more)
    • Strategic implications: Invest in antigen‑directed sequencing (DLL3→SEZ6/B7‑H3), manage overlapping toxicities (Topo‑I payloads, IL‑2 add‑ons), and build diagnostic access (SEZ6/DLL3) to capture broad SCLC segments. (read more)
Publications Related to Approved Drugs
Phase 3
durvalumab
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial. Exploratory analyses from the ADRIATIC trial show that consolidation durvalumab significantly improved overall and progression-free survival in limited-stage SCLC patients post-concurrent chemoradiotherapy (cCRT), compared to placebo. This clinical benefit was consistent across various subgroups, irrespective of the specific cCRT components, use of prophylactic cranial irradiation (PCI), or timing from cCRT completion, reinforcing its new standard-of-care role in this setting. ()
New Publications Related to Drugs in Clinical Trial Development
N/A
Toward uncertainty-aware clinical decision support for treatment response prediction in metastatic NSCLC: integrating FDG-PET, T-cell repertoire, and cytokines with conformal prediction. A multimodal framework combining longitudinal FDG-PET, T-cell receptor, and cytokine biomarkers significantly outperformed the standard PD-L1 tumor proportion score in predicting early treatment response in metastatic non-small cell lung cancer (NSCLC). This integrated approach, prototyped in a clinical decision support interface, offers a more reliable and uncertainty-quantified method for guiding patient care. ()
Phase 1
SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial. The novel Seizure-related homolog 6 (SEZ6)-targeting antibody-drug conjugate, ABBV-706, demonstrated promising preliminary efficacy in a phase 1 trial for relapsed/refractory small cell lung cancer (SCLC), achieving an objective response rate (ORR) of 52%. Based on a favorable balance of safety, tolerability, and durable tumor reduction, 1.8 mg kg-1 administered every 3 weeks was established as the optimal recommended phase 2 dose. ()
Phase 3
First-Line Sunvozertinib in NSCLC with <i>EGFR</i> Exon 20 Insertion Mutations. In a phase 3 trial for advanced NSCLC with <i>EGFR</i> exon 20 insertions, first-line treatment with sunvozertinib resulted in significantly longer median progression-free survival (10.3 months) compared to chemotherapy (7.5 months). This supports the superior efficacy of sunvozertinib as a first-line standard of care for this specific patient population. ()
Phase 3
Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial. For patients with treatment-naive, <i>EGFR</i>-mutated advanced NSCLC harboring concurrent <i>TP53</i> mutations, first-line osimertinib plus chemotherapy significantly prolonged median progression-free survival to 34.0 months compared to 15.6 months with osimertinib monotherapy. These findings provide a strong clinical rationale for adopting this combination strategy to manage this high-risk patient subgroup. ()
Phase 2
Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial. The irreversible EGFR-TKI sutetinib demonstrated clinically meaningful antitumor activity in a phase IIb trial for advanced NSCLC with uncommon <i>EGFR</i> mutations (G719X, S768I, L861Q), achieving a confirmed objective response rate of 70.8% and a median progression-free survival of 13.7 months. These results position sutetinib as a potential new treatment option for this molecularly diverse patient population. ()
Phase 3
Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial. Adjuvant crizotinib did not prolong disease-free survival in patients with surgically resected, early-stage <i>ALK</i>-positive NSCLC compared to observation, with a median DFS of 74.6 months versus 106.2 months, respectively. These findings indicate that crizotinib should not be recommended as an adjuvant therapy in this setting. ()
Phase 2
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD. In patients with <i>EGFR</i>-mutated advanced NSCLC that transformed to neuroendocrine carcinoma after progressing on first-line osimertinib, treatment with durvalumab plus etoposide-platinum demonstrated modest clinical activity. The combination yielded a confirmed objective response rate of 43% and a median overall survival of 10.2 months, with a safety profile consistent with the individual agents. ()
Phase 2
Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study. The HYPERBOLIC study is the first prospective, biomarker-driven trial designed to mitigate hyperprogressive disease (HPD) in PD-L1-high NSCLC by evaluating whether adding three cycles of chemotherapy to first-line cemiplimab reduces the rate of HPD and early death. The trial uses high baseline levels of circulating CD10- low-density neutrophils as a biomarker to identify patients at high risk for HPD. ()
Phase 3
Selpercatinib in Early-Stage <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer. Adjuvant selpercatinib significantly improved event-free survival compared to placebo in patients with resected stage II-IIIA <i>RET</i> fusion-positive NSCLC, with a 2-year event-free survival rate of 92% versus 61%, respectively. These results establish a new standard of care for this patient population, demonstrating the benefit of targeted therapy in the early-stage setting. ()
Phase 3
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. In patients with resected NSCLC without sensitizing <i>EGFR/ALK</i> alterations, adjuvant nivolumab administered after standard adjuvant therapy did not improve disease-free survival compared to observation. The trial was stopped for futility, indicating that adjuvant nivolumab monotherapy is not beneficial in this setting. ()
PHASE1,PHASE2
Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study. The first-in-human study of rilvegostomig, an anti-PD-1/TIGIT bispecific antibody, showed a favorable tolerability profile and evidence of clinical efficacy in heavily pretreated, CPI-experienced patients with advanced or metastatic NSCLC. At the recommended phase II dose, the 12-month progression-free survival was 11.9%, supporting further evaluation in CPI-naïve patient populations. ()
Phase 2
Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9. The combination of enfortumab vedotin and pembrolizumab demonstrated promising clinical activity as a first-line treatment for patients with PD-L1 positive (CPS ≥1) recurrent or metastatic head and neck squamous cell carcinoma. The therapy achieved a confirmed objective response rate of 39% with a manageable safety profile, suggesting a potential new standard of care. ()
Phase 1
T cell receptor repertoire dynamics and newly identified functional regulators of autologous tumor-infiltrating lymphocyte therapy in advanced solid tumors. This phase I trial of autologous tumor-infiltrating lymphocyte (TIL) therapy in Asian patients with diverse advanced solid tumors demonstrated an objective response rate of 33.3% and identified ASS1 and CEP20 as genes negatively associated with efficacy. CRISPR/Cas9-mediated knockout of these genes enhanced TIL antitumor function, providing a potential strategy to improve TIL therapy for broader clinical application. ()
Phase 2
A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study. The combination of encorafenib and binimetinib confirmed significant clinical benefit for Chinese patients with BRAFV600E-mutated metastatic NSCLC, achieving a confirmed objective response rate of 61% by independent central review. The study reported a median progression-free survival of 13.8 months and a median overall survival of 27.9 months, with no new safety concerns identified in this population. ()
Phase 3
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study. After five years of follow-up, the KEYNOTE-671 study demonstrated durable and clinically meaningful benefits of adding perioperative pembrolizumab to neoadjuvant chemotherapy for resectable early-stage NSCLC. The 5-year event-free survival was nearly doubled at 49.9% with pembrolizumab versus 26.5% with placebo, supporting this regimen as a standard of care. ()
Phase 3
Biomarkers of nivolumab benefit in resectable non-small cell lung cancer. In the CheckMate 77T study, exploratory biomarker analysis revealed that pre-surgical clearance of circulating tumor DNA (ctDNA) was a strong predictor of prolonged event-free survival (EFS) with perioperative nivolumab in resectable NSCLC. These findings provide key insights into predictive markers for outcomes and may help refine patient selection for neoadjuvant immunotherapy. ()
Phase 3
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial. This secondary analysis of the ASTRUM-005 trial confirms the long-term, substantial survival benefit of adding serplulimab to first-line chemotherapy for extensive-stage SCLC, with a median overall survival of 15.8 months versus 11.1 months for placebo. The 4-year overall survival rate of 21.9% for the serplulimab arm, compared to 7.2% for placebo, reinforces this combination as a first-line standard of care. ()
Phase 1
Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318. In three phase 1 studies of oral small-molecule PD-L1 inhibitors, INCB099280 and INCB099318 demonstrated acceptable safety profiles and preliminary antitumor activity in patients with advanced solid tumors, with objective response rates around 8.8%. These findings support the potential of oral PD-L1 inhibitors to improve convenience and access, while the clinical program for INCB086550 was discontinued due to immune-mediated neuropathy risk. ()
Phase 3
RATIONALE-303: Long-Term Outcomes of Tislelizumab in Previously Treated Advanced/Metastatic NSCLC. With an extended follow-up of nearly four years, the RATIONALE-303 trial confirmed that tislelizumab provides clinically meaningful and durable improvements in overall survival compared to docetaxel for previously treated advanced NSCLC. The median overall survival was 16.9 months with tislelizumab versus 11.9 months with docetaxel, coupled with a more favorable long-term safety profile. ()
Phase 3
Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin® and US-Avastin® in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer. A unified population pharmacokinetic model demonstrated that the bevacizumab biosimilar CT-P16 has comparable pharmacokinetics to both EU- and US-sourced reference Avastin®. This analysis, which integrated data from healthy subjects and NSCLC patients, supports the biosimilarity of CT-P16 and illustrates how such modeling can streamline biosimilar assessment. ()
Phase 3
SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation. The SKYSCRAPER-03 study did not meet its primary endpoint, as consolidation therapy with tiragolumab plus atezolizumab did not improve progression-free or overall survival compared to durvalumab alone in patients with unresectable, stage III NSCLC. While the combination was tolerated, it offered no additional clinical benefit over the current standard of care. ()
Phase 2
Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial. The combination of anlotinib plus penpulimab shows promising antitumor activity as a second-line treatment for platinum-resistant extensive-stage SCLC, achieving a confirmed objective response rate of 41.5% and a median overall survival of 10.5 months. These findings suggest a potential new therapeutic option for this patient population with limited choices, with exploratory ctDNA analysis indicating that lower baseline somatic allele frequency is associated with improved survival. ()
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in small cell lung cancer updated from 2026-08-01 to 2026-08-31:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation-------
Not Yet Recruiting231434127
Recruiting4446626475210
Available-------
Approved for Marketing-------
Active, Not Recruiting171628332197
Completed4-5-3-12
Total676510912867346
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
LOXO-260 NCT05241834 COMPLETED A Phase 1 Study of Oral LOXO-260 in Patients With RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation Refractory to Selective RET Inhibitors 2026-06-03
AMG 355, Pembrolizumab NCT06131398 COMPLETED A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors 2026-07-22
Tislelizumab SC, Histology-Based Chemotherapy Doublet, Tislelizumab IV NCT06091943 COMPLETED Phase 1 Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in the First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer 2026-08-04
Zirconium Zr 89 crefmirlimab berdoxam NCT06863233 COMPLETED Assessment of Patients Immune Response After Treatment With Engineered Tumor Infiltrating Lymphocyte Therapy Incorporating CD8 PET Imaging 2026-08-24
Docetaxel, AB801 NCT06120075 ACTIVE_NOT_RECRUITING A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies 2026-11
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
furmonertinib NCT06812871 COMPLETED A Single-arm, Multicenter, Phase 2 Study of High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis 2026-06-30
irinotecan liposome, ivonescimab NCT06478043 COMPLETED Phase II Study of AK112 Combined With Irinotecan Liposome in Patients With SCLC Who Progressed on Immune Checkpoint Inhibitors and Chemotherapy. 2026-06-30
induction chemo-immunotherapy, Thymosin Alpha1, Immunotheapy consolidation, concurrent chemotherapy NCT06139419 COMPLETED A Prospective Phase II Controlled Study to Evaluate the Impact of Thymosin Alpha 1 on the Completion Rate of Consolidation Immunotherapy After Radical Radiochemotherapy for Locally Advanced Non-Small Cell Lung Cancer 2026-06-30
Tislelizumab NCT05758116 COMPLETED A Prospective, Open-label, Single-arm, Phase II Trial Investigating the Efficacy and Safety of Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients 2026-06-30
Tepotinib, Osimertinib NCT03940703 COMPLETED A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2) 2026-07-15
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
pemetrexed, cisplatin, etoposide, carboplatin, : durvalumab, paclitaxel, : pembrolizumab/vibostolimab NCT05298423 COMPLETED Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC 2026-06-15
: CS1001 monoclonal antibody NCT03789604 COMPLETED A Multi-Center, Randomized, Double-Blind, Phase III Study of Platinum-Containing Chemotherapy With or Without CS1001 in Stage IV Non-Small Cell Lung Cancer Subjects 2026-07-01
Pemetrexed, Carboplatin, Cisplatin, Alectinib NCT06624059 COMPLETED A Phase I-II, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients With Resectable Stage I-III Non-Small Cell Lung Cancer, Selected According to Biomarker Status 2026-07-31
docetaxel, JDQ443 NCT05132075 ACTIVE_NOT_RECRUITING A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer 2026-09-23
Docetaxel, MRTX849 NCT04685135 ACTIVE_NOT_RECRUITING A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation 2026-10-30
Osimertinib, Pemetrexed, Carboplatin, Savolitinib, Cisplatin NCT05261399 ACTIVE_NOT_RECRUITING A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON). 2026-11-23
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
No phase 4 trials completing within the next three months.
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.